This Viewpoint discusses the implementation and subsequent deimplementation of safer supply programs in Canada, which provided access to pharmaceutical-grade medications for individuals who use unregulated substances, particularly opioids.
Karamouzian et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: